Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile ...
Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.
Highlighted Terms
Centers for Disease Control and PreventionCRS3123National Institute of Allergy and Infectious DiseasesLeeds Teaching HospitalsNational Institute of Allergy and Infectious DiseasesUniversity of LeedsNational Institutes of HealthCenters for Disease Control and PreventionvancomycinClostridioides difficile infectionCrestone, Inc.Department of Health and Human ServicesNIAIDCDICDCUK Health Security AgencyLeeds Teaching HospitalsCRS3123University of CalgaryUniversity of LeedsvancomycinNIAIDUK Health Security AgencyCrestone, Inc.Clostridioides difficile infectionUniversity of CalgaryCDCCDI
Related News
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
Crestone announces positive Phase 2 results for CRS3123 in treating C. difficile infections (CDI), showing high clinical cure rates and lower recurrence compared to vancomycin. CRS3123, a novel drug, maintains gut microbiota, addressing urgent need for effective CDI therapy.
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile ...
Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.